These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 23426122

  • 21. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D, Luger S, Schuster S, Stadtmauer E.
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [Abstract] [Full Text] [Related]

  • 22. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 23. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [Abstract] [Full Text] [Related]

  • 24. Composite lymphoma of the orbit treated with rituximab.
    Kang SJ, Schmack I, Wojno TH, Grossniklaus HE.
    Ophthalmic Plast Reconstr Surg; 2007 Jan; 23(2):143-4. PubMed ID: 17413631
    [Abstract] [Full Text] [Related]

  • 25. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
    Duman BB, Sahin B, Ergin M, Guvenc B.
    Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
    [Abstract] [Full Text] [Related]

  • 26. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ, Wang FH, Huang HQ, Luo HY, Li YH, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
    [Abstract] [Full Text] [Related]

  • 27. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A.
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V, GOELAMS group.
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [Abstract] [Full Text] [Related]

  • 30. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L, Wang W, Li X, Guo Y, Zhu X.
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [Abstract] [Full Text] [Related]

  • 31. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 32. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE.
    Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
    [Abstract] [Full Text] [Related]

  • 33. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM, Freeman JK, Steingart RH, Hasserjian RP.
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [Abstract] [Full Text] [Related]

  • 34. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
    Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, Kiyoi H, Asano N, Nakamura S, Kinoshita T, Naoe T.
    Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
    [Abstract] [Full Text] [Related]

  • 35. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF.
    Cancer; 2006 Jun 01; 106(11):2412-20. PubMed ID: 16649223
    [Abstract] [Full Text] [Related]

  • 36. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M.
    Ann Hematol; 2011 Feb 01; 90(2):185-92. PubMed ID: 20809421
    [Abstract] [Full Text] [Related]

  • 37. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T.
    Eur J Haematol; 2011 Feb 01; 86(2):117-23. PubMed ID: 21070370
    [Abstract] [Full Text] [Related]

  • 38. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
    Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M.
    Am J Clin Pathol; 2001 Sep 01; 116(3):437-43. PubMed ID: 11554173
    [Abstract] [Full Text] [Related]

  • 39. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S.
    Oncol Rep; 2011 Apr 01; 25(4):1183-90. PubMed ID: 21318224
    [Abstract] [Full Text] [Related]

  • 40. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K, Terui Y.
    Gan To Kagaku Ryoho; 2009 Apr 01; 36(4):548-51. PubMed ID: 19381025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.